Sepsis is one of the most dangerous conditions in modern medicine. In cases of systemic infection, the countdown is often measured not in days but in hours. The faster clinicians receive information about the causative pathogen and its susceptibility to antimicrobial agents, the higher the chances of successful patient treatment.
In bloodstream infections, clinicians need answers to two key questions as early as possible:
• Which microorganism is causing the infection?
• Which antibiotics is it susceptible to?
Traditional microbiological methods often require several days to provide a complete picture. In cases of sepsis, this timeframe may be too long.
Modern molecular diagnostic technologies and rapid antimicrobial susceptibility testing significantly reduce the time required to establish a diagnosis and initiate targeted therapy.
hyborg Dx RED2: Rapid Pathogen Identification
When a patient is in critical condition, clinicians need to identify the causative pathogen as quickly as possible.
hyborg Dx RED2 is an automated molecular diagnostic system that enables pathogen identification directly from clinical specimens without prior cultivation.
The system works with:
• Whole blood
• Positive blood cultures
• Bronchoalveolar lavage (BAL) samples
• Tissue specimens
What does the system detect?
A single test can simultaneously identify more than 100 targets, including:
• Bacteria
• Fungi
• Antimicrobial resistance genes
Only 0.5 mL of whole blood is required for analysis, making the system particularly valuable in neonatology and pediatrics.
Unlike conventional methods that require lengthy cultivation, hyborg Dx RED2 provides pathogen identification in less than three hours, significantly accelerating the initiation of targeted therapy.
dRAST: Rapid Selection of the Effective Antibiotic
Once the microorganism has been identified, the next step is selecting the most appropriate treatment. dRAST is designed specifically for this purpose. It is a solution for direct phenotypic antimicrobial susceptibility testing from positive blood cultures.
Key capabilities of dRAST
The system provides:
• Determination of Minimum Inhibitory Concentration (MIC)
• Results in as little as 4 hours
• No requirement for pure isolate preparation
• Simultaneous testing of up to 12 samples
• Dedicated panels for Gram-positive and Gram-negative microorganisms
• Interpretation according to CLSI or EUCAST standards
Thanks to its phenotypic approach, the laboratory obtains information about the actual response of the pathogen to antimicrobial agents, helping clinicians select the most effective treatment.
Two Technologies — One Clinical Outcome
Effective sepsis treatment begins with two key answers:
Which pathogen is causing the infection?
→ hyborg Dx RED2
Which antibiotic will be effective?
→ dRAST
Together, these technologies enable a rapid transition from diagnosis to personalized therapy, helping clinicians make informed decisions in the shortest possible time.
Clinical Benefits for Healthcare Facilities
Implementing rapid sepsis diagnostics provides several important advantages:
• Reduced patient length of stay in intensive care units
• More rational use of reserve antibiotics
• Reduced risk of healthcare-associated infections
• Improved laboratory workflow efficiency
In addition to clinical benefits, hospitals gain opportunities to optimize resource utilization and reduce the costs associated with treating severe infections.
The Future of Bacteriology: Rapid Solutions for Critical Conditions
Modern microbiology is gradually moving from multi-day waiting periods toward rapid, personalized diagnostics. For patients with sepsis, this means faster identification of the cause of infection and timely initiation of effective treatment.
The combination of molecular pathogen identification using hyborg Dx RED2 and rapid antimicrobial susceptibility testing using dRAST opens new opportunities for laboratories seeking to operate according to modern international standards.
Need a Consultation?
The specialists at Empirica Medical Company will help assess the possibilities of implementing hyborg Dx RED2 and dRAST systems in your laboratory and select the solution that best meets the needs of your healthcare facility.
Contact Information
Phone: +38 (044) 223 14 06
Email: office@empirica.healthcare
